| WARF: P92190US |  |
| Novel Use of 1 Alpha-Hydroxylated-19-Nor-Vitamin D Compounds To Treat Psoriasis |
| INVENTORS | • | Hector DeLuca |
OVERVIEW
A novel use for 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1 alpha, 25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell line.
ADDITIONAL INFORMATION
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Skin & connective tissue
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
